Premier Alternatives

Grannus Therapeutics

Indianapolis, IN · Founded 2020 · Privately Held (backing)

Operator of a pre-clinical stage biotechnology company intended to support a cancer treatment. Grannus Therapeutics is based in Indianapolis, IN and was founded in 2020. It was valued at $5 million at its seed round in Jan 2022, the last priced event on record. It has raised $2.9 million across 2 recorded rounds; the latest was an $800,000 debt round in Nov 2023.

PMV mark · valuation
$5.0M
Oct 2026
Priced at
its seed round
Jan 2022
Total raised
$2.9M
Last round
Debt
Nov 2023

Grannus Therapeutics key facts

as of Oct 2026
  • Operator of a pre-clinical stage biotechnology company intended to support a cancer treatment.
  • Grannus Therapeutics is valued at approximately $5.0M as of Oct 2026, set at its seed round, Jan 2022; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $2.9M across 2 recorded rounds; the latest was Debt ($800K) in Nov 2023.
  • Notable investors include Plug and Play Tech Center, Elevate Ventures, 1842 Fund, Economic Development Corporation, National Cancer Institute — 7 tracked in total.
  • Grannus Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Jan 2024 ($800K sold to 9 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$5.0M

Valued at $5.0M at its seed round, Jan 2022. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Grannus Therapeutics with a free account
  • ·Watch Grannus Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Grannus Therapeutics funding rounds

2 rounds
Nov 2023Debt$800KSEC filing▮
Jan 2022Seed Round$950KSEC filing▮
Full funding history →

Grannus Therapeutics valuation

Grannus Therapeutics was valued at $5 million at its seed round in Jan 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Grannus Therapeutics raised?

Grannus Therapeutics has raised $2.9 million in total; 2 of its rounds are on record. The largest on record was a $950,000 seed round in Jan 2022; the most recent was an $800,000 debt round in Nov 2023.

Grannus Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently in Jan 2024 ($800,000 sold to 9 investors).

Grannus Therapeutics investors

7 investors are on record for Grannus Therapeutics, including Plug and Play Tech Center, Elevate Ventures, 1842 Fund and Economic Development Corporation. The debt round in Nov 2023 drew 9 investors.

About Grannus Therapeutics

Operator of a pre-clinical stage biotechnology company intended to support a cancer treatment. The company develops a molecule that selectively inhibits specific isoforms of Hsp90, addresses the toxicity and dosing challenges that pan-inhibitors experienced in oncology clinical trials, and expands the therapeutic potential of the Hsp90 target to other therapeutic areas, enabling healthcare professionals to treat multiple types of cancers

Sector
Healthcare
HQ
Indianapolis, IN, United States
Founded
2020
Employees
2
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.